Pulmonary arterial hypertension (PAH) is a syndrome in which pulmonary arterial obstruction increases pulmonary vascular resistance, leading to right ventricular hypertrophy (RVH), failure, and death. The development of small-animal preclinical models of PAH is a necessary challenge in order to test the efficacy of new...
In the framework of our development, we are proud to announce the recruitment of our new scientific colleague, Guénaelle CANET. She will work in our Technical Department at the Lab and will be in charge, with the scientific and technical team, of setting up different...
Researchers from the college of Pharmaceutical Sciences in China have recently studied a compound that enhances neuronal recovery in a rat model of Parkinson’s disease (Parkinson 6 OHDA). Parkinson’s disease is a chronic disorder of the central nervous system, caused primarily by the progressive loss...
Emesis and/or Nausea are commonly reported side effects associated with several drugs such as 4 phosphodiesterase (PDE4) inhibitors and is a major drawback for the therapeutic use of these drugs. The mechanism responsible for this side effect has been investigated in an attempt to discover...
Syncrosome invites you to visit us at Bio-Europe, November 7th to November 9th 2016, in Cologne, Germany. Emmanuelle Bettendorf, our Business Developer would be delighted to meet you their and discuss your in vivo preclinical projects. We can give you advice about our in vivo efficacy, CNS-PK...
The 2nd Drug Discovery Innovation Programme will feature 2 days of interactive presentations, poster presentation and networking opportunity, in Hamburg (Germany) from 20 to 21st of October. This conference will offer a complete programme focusing on preclinical animal models, breakthrough technologies, in vivo and in...
Syncrosome, participated last week to the Neuroscience R&D Technologies Conference in London, to present key Parkinson's data. It was 2 very interesting days spent to discuss about the new advances in Imaging of Neurodegeneration, Alzheimer and Parkinson’s Disease and Drug Discovery, New trends in Preclinical animal...
L-DOPA remains the most effective therapy in the management of the motor symptoms of Parkinson's disease (PD). However, chronic treatment with levodopa is associated with the risk of development of motor fluctuations such as choreic and dystonic abnormal and involuntary movements affecting mainly the upper...
As you know Syncrosome is a preclinical CRO managing efficacy in vivo/ in vitro studies with more than 15 disease models validated in house and reproducible. Syncrosome is involved in Central Nervous System activities for 16 years with a specific department dedicated to several CNS disease...
Syncrosome is just launching its new website. This is the result of the collaboration between Syncrosome’s internal team, consultants and customers: www.syncrosome.com. Thank you for your collaboration, and we hope you will find all information you are looking for! Please do not hesitate to visit it and...